EFFECT OF GLUCOCORTICOID THERAPY FOR CONGENITAL ADRENAL HYPERPLASIA IN ADULT PATIENTS ON REDUCTION OF BONE MINERAL DENSITY
https://doi.org/10.14341/osteo2014226-28
Abstract
Congenital adrenal hyperplasia (CAH) is a disease leading to decreased adrenal cortisol secretion which requires lifelong treatment with glucocorticoids (GC). However the question whether these patients need regular DXA screening for osteoporosis is still widely discussed in literature. The aim of this study was to evaluate bone mineral density (BMD) in adult patients with classical forms of CAH in Russian population. We have shown that 22% of patients had low BMD which had no correlation with compensation and GC doses. There were no significant deviations in biochemical markers of bone turnover levels. The serum Vitamin D deficiency was found in 89% of patients with CAH which needed early correction in patients with low BMD.
References
1. Eastell, R. (1995) Management of corticosteroid-induced osteoporosis. Journal of Internal Medicine, 237, 439-447;
2. Zelissen P.M., Croughs R.J., van Rijk P.P., Raymakers J.A. 1994 Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120: 207-210;
3. Bachelot A., Chakhtoura Z., Samara-Boustani D., Dulon J., Touraine P., Polak M. Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency. Int J Pediatr Endocrinol. 2010;
4. Bachelot A., P-Bureau G., Thibaud E., Laborde K., Pinto G., Samara D., Nihoul-Fékété C., Kuttenn F., Polak M., Touraine P.: Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2006; 67: 268-276;
5. Jaaskelainen J., Voutilainen R.: Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1996; 45: 707-713;
6. King J.A., Wisniewski A.B., Bankowski B.J., Carson K.A., Zacur H.A., Migeon C.J.: Long term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006; 9: 865-869;
7. Sciannamblo M., Russo G., Cuccato D., Chiumello G., Mora S.: Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4453-4458;
8. Paganini C., Radetti G., Livieri C., Braga V., Migliavacca D., Adami S.: Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm Res 2000; 54: 164-168;
9. Girgis R., Winter J.S.: The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997; 82: 3926-3929;
10. Guo C.Y., Weetman A.P., Eastell R.: Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1996; 45: 535-541;
11. Gussinye M., Carrascosa A., Potau N., Enrubia M., Vicens-Calvet E., Ibanez L., Yeste D.: Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 1997; 100: 671-674.
Review
For citations:
Sazonova A.I., Molashenko N.V., Troshina E.A. EFFECT OF GLUCOCORTICOID THERAPY FOR CONGENITAL ADRENAL HYPERPLASIA IN ADULT PATIENTS ON REDUCTION OF BONE MINERAL DENSITY. Osteoporosis and Bone Diseases. 2014;17(2):26-28. (In Russ.) https://doi.org/10.14341/osteo2014226-28
Views:
1180
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
